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ABSTRACT
The aim of the present study was to examine the efficacy of tumor-targeting 
Salmonella typhimurium A1-R treatment following anti-vascular endothelial growth 
factor (VEGF) therapy on VEGF-positive human pancreatic cancer. A pancreatic cancer 
patient-derived orthotopic xenograft (PDOX) that was VEGF-positive and an orthotopic 
VEGF-positive human pancreatic cancer cell line (MiaPaCa-2-GFP) as well as a VEGF-
negative cell line (Panc-1) were tested. Nude mice with these tumors were treated 
with gemcitabine (GEM), bevacizumab (BEV), and S. typhimurium A1-R. BEV/GEM 
followed by S. typhimurium A1-R significantly reduced tumor weight compared to 
BEV/GEM treatment alone in the PDOX and MiaPaCa-2 models. Neither treatment was 
as effective in the VEGF-negative model as in the VEGF-positive models. These results 
demonstrate that S. typhimurium A1-R following anti-angiogenic therapy is effective 
on pancreatic cancer including the PDOX model, suggesting its clinical potential.
INTRODUCTION
Pancreatic cancer is one of the most aggressive 
malignant tumors with a 23 % 1-year survival rate and 
< 2 % 5-year survival rate. The two most commonly 
used chemotherapy drugs approved for the treatment 
of pancreatic cancer are gemcitabine (GEM) and 
5-fluorouracil (5-FU). In recent years, little progress has 
been made in understanding and treatment of this disease 
[1].
In pancreatic cancer, overexpression of vascular 
endothelial growth factor (VEGF) and its receptors is 
associated with poor prognosis and increased metastatic 
potential [2, 3]. Bevacizumab (BEV) is a humanized 
monoclonal VEGF-neutralizing antibody that many 
tumors become resistant to after a short period of response 
[4].
Our laboratory has previously developed a 
genetically modified bacterial strain, Salmonella 
typhimurium A1, selected for anticancer activity in vivo. 
S. typhimurium A1 is auxotrophic (leu/arg-dependent) [5]. 
The strain targets and grows in tumors. In contrast, normal 
tissue is cleared of these bacterial even in immunodeficient 
athymic mice. In order to increase the tumor-targeting 
capability of A1, the strain was re-isolated after infection 
of a human colon tumor growing in nude mice. The 
tumor-isolated strain, termed S. typhimurium A1-R, had 
increased targeting for cells in vivo as well as in vitro [6].
S. typhimurium A1-R is effective against prostate 
cancer [7], breast cancer [6, 8], pancreatic cancer [9-12], 
glioma [13, 14], lung cancer [15], fibrosarcoma [16] and 
osteosarcoma [17].
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In the present study, we demonstrate the efficacy of 
S. typhimurium A1-R following antiangiogenic therapy 
with bevacizumab/gemcitabine (BEV/GEM) in patient-
derived orthotopic xenograft (PDOX) and cell line nude-
mouse models of pancreatic cancer.
RESULTS AND DISCUSSION
Differential expression patterns of VEGF-related 
genes in pancreatic cancer cell lines
In order to identify potential BEV-sensitive 
pancreatic cancer cell lines, mRNA expression of VEGFA, 
VEGFR1 and VEGFR2 in pancreatic cancer cell lines 
(BxPC-3, Capan-1, Hs766T, MiaPaCa-2 and Panc-1) 
was examined by real-time RT-PCR (Fig. 1). MiaPaCa-2 
expressed VEGFA significantly more than other cell lines 
(p < 0.001) except for BxPC-3 (p = 0.558) (Fig. 1A). 
MiaPaCa-2 expressed VEGFR2 significantly more than 
other cell lines (BxPC-3: p = 0.005; Capan-1: p < 0.001; 
Hs766T: p = 0.005; and Panc-1: p = 0.006) (Fig. 1C). 
VEGFR1 expression was not detected in MiaPaCa-2 and 
Capan-1 cell lines (Fig. 1B).
S. typhimurium A1-R killed MiaPaCa-2 and Panc-
1 pancreatic cancer cells in vitro
GFP-expressing S. typhimurium A1-R invaded 
MiaPaCa-2 and Panc-1 pancreatic cancer cells as early as 
60 min, and replicated in the cells 120 min after infection. 
Both cancer cell types appeared to die via apoptosis 24 hr 
after bacterial infection (Fig. 2A). In the clonogenic assay, 
the average colony area of MiaPaCa-2 treated with S. 
typhimurium A1-R was 2.95 ± 0.84 mm2 compared to the 
untreated control, 6.03 ± 0.86 mm2. The average colony 
area of Panc-1 treated with S. typhimurium A1-R was 0.93 
± 0.31 mm2, compared to the untreated control, 1.91 ± 0.10 
mm2. S. typhimurium A1-R significantly reduced colony 
formation of both pancreatic cancer cell lines compared to 
the control (MiaPaCa-2: p = 0.001 and Panc-1: p < 0.001) 
(Fig. 2B and 2C). 
Differential sensitivity to BEV in pancreatic 
cancer cell lines growing subcutaneously in nude 
mice
Real-time RT-PCR of VEGF-related gene expression 
(Fig. 1) predicted that MiaPaCa-2 was BEV-sensitive 
and Panc-1 was BEV-resistant. The efficacy of BEV on 
these cell lines was first determined using a subcutaneous 
tumor mouse model (Fig. 3). The average tumor volume 
Figure 1: mRNA expression of VEGFA (A), VEGFR1 (B) and VEGFR2 (C) in pancreatic cancer cell lines. mRNA 
expression was determined with real-time RT-PCR. MiaPaCa-2 significantly expressed VEGFA more than the  other cell lines (p < 0.001) 
except for BxPC-3 (p = 0.558) (A). MiaPaCa-2 significantly expressed VEGFR2 more than other cell lines (BxPC-3: p = 0.005, Capan-1: 
p < 0.001; Hs766T: p = 0.005; and Panc-1: p = 0.006) (C). VEGFR1 expression was not detected in MiaPaCa-2 and Capan-1 cell lines (B). 
Data for each treatment are represented as the mean ± SD. ** p < 0.01.
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of the MiaPaCa-2 tumors treated with BEV was 1.04 ± 
0.24 mm3  compared to the control which was 4.19 ± 1.21 
mm3 on Day 22. The average tumor volume of the Panc-1 
tumors treated with BEV was 5.50 ± 2.62 mm3 compared 
to the control which was 5.28 ± 0.99 mm3 on Day 22. BEV 
significantly reduced the growth of MiaPaCa-2 compared 
to the untreated control group on Day 22 (p < 0.001) but 
did not reduce the growth of Panc-1 (Fig. 3).
Efficacy of BEV on microvessel density in 
pancreatic cell lines growing subcutaneously in 
mice
Subcutaneous tumors (MiaPaCa-2 or Panc-1) were 
treated with BEV (5 mg/kg, twice a week for 2 weeks) 
and tumor samples were removed 7 days after the last 
treatment. Frozen sections from each tumor were stained 
with anti-mouse CD31 antibody, and the MVD was 
Figure 2: Efficacy of S. typhimurium A1-R on pancreatic cancer cell lines. (A) Confocal imaging of MiaPaCa-2 and Panc-1 pancreatic 
cancer cells infected with S. typhimurium A1-R in vitro. S. typhimurium A1-R infection was detected in both pancreatic cancer cell types 
after 60 min. S. typhimurium A1-R replicated in the cells after 120 min. S. typhimurium A1-R showed the ability to infect and induce 
apoptosis in both cell types after 24 hr. Scale bars: 100 μm (pre); 50 μm (60 and 120 min); 25 μm (24 hr). (B and C) MiaPaCa-2 and Panc-1 
were treated with S. typhimurium A1-R. Clonogenic assays show that S. typhimurium A1-R significantly reduced colony formation of both 
pancreatic cancer cell lines compared to the control groups in vitro (MiaPaCa-2: p = 0.001 and Panc-1: p < 0.001). ** p < 0.01.
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determined by counting three fields at ×100 magnification 
of the highest vascular density. The average MVD of the 
MiaPaCa-2 tumors treated with BEV was 27.6 ± 7.45 
compared to the control which was 65.1 ± 16.5. The 
average MVD of the Panc-1 tumors treated with BEV was 
52.4 ± 8.43 compared to the control which was 57.4 ± 5.81. 
BEV significantly reduced the MVD of the MiaPaCa-2 
tumor compared to the control (p = 0.002) (Fig. 4A, B, 
E) but did not significantly reduce MVD of the Panc-1 
tumor (Fig. 4C, D, F). These results are consistent with 
the expression levels of VEGF-related genes (Fig. 1), 
indicating that MiaPaCa-2 is BEV-sensitive and Panc-1 
is BEV-resistant.
Figure 3: Efficacy of BEV treatment on pancreatic cancer cell lines which have different levels of VEGFA and VEGFR2 
expression. (A) Schema of treatments on subcutaneous tumors. Based on RT-PCR results, MiaPaCa-2 was determined to be VEGFA-
positive and VEGFR2-positive. Panc-1 was determined as VEGFA-negative and VEGFR2-negative. In order to determine the efficacy of 
BEV on pancreatic cancer cell lines with different levels of VEGFA and VEGFR2 expression, subcutaneous tumors from MiaPaCa-2 and 
Panc-1 cells were grown in nude mice and randomized to 3 groups as described in the Materials and Methods. (B) BEV significantly reduced 
the growth of the MiaPaCa-2 tumor compared to the control on Day 22 (p < 0.001). Both BEV → GEM and BEV → S. typhimurium A1-R 
treatments significantly reduced MiaPaCa-2 tumor growth compared to the control group on Day 43 (p = 0.001). BEV → S. typhimurium 
A1-R significantly reduced the MiaPaCa-2 tumor growth compared to BEV → GEM (p = 0.037). (C) BEV did not reduce the tumor growth 
of Panc-1 compared to the control on Day 22, but both BEV → GEM and BEV → S. typhimurium A1-R treatment significantly reduced 
tumor growth compared to the control on Day 43 (BEV → GEM: p = 0.023; BEV → S. typhimurium A1-R: p = 0.026). * p < 0.05.
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Efficacy of S. typhimurium A1-R following BEV 
treatment on growth of BEV-sensitive and 
-resistant tumors
For the BEV-sensitive MiaPaCa-2 tumor, both BEV 
→ GEM and BEV → S. typhimurium A1-R significantly 
reduced tumor growth compared to the controls on Day 
43 (p = 0.001). BEV→S. typhimurium A1-R significantly 
reduced tumor growth compared to BEV → GEM (p 
= 0.037) (Fig. 3B). S. typhimurium A1-R completely 
suppressed growth of MiaPaCa-2 after BEV treatment 
(Fig. 3B). Both BEV → GEM and BEV →S. typhimurium 
A1-R significantly reduced tumor growth of the BEV-
resistant tumor Panc-1 compared to the control (BEV → 
GEM: p = 0.023; BEV →S. typhimurium A1-R: p = 0.026) 
but to a lesser extent than MiaPaCa-2 (Fig. 3C). There 
was no significant difference in tumor growth inhibition 
between BEV →S. typhimurium A1-R and BEV →GEM.
Furthermore, GFP-labeled S. typhimurium A1-R 
Figure 4: Microvessel density (MVD) in s.c. pancreatic cancer xenografts in nude mice treated with bevacizumab (BEV). To 
determine MVD, sections were stained with an antibody to CD31 as described in the Materials and Methods. MVD was determined by 
counting the number of CD31-positive vessels in three fields at ×100 magnification of the highest vascular density. The values are the 
average numbers of microvessels ± S.D. (bars) of five different tumors. (A-D) Representative images of frozen sections stained with anti-
CD31 antibody. The number of vessels in MiaPaCa-2 tumors treated with BEV (B) was reduced compared to the control (A). In contrast, 
there was no difference between Panc-1 tumors treated with BEV (D) and control (C). Scale bars: 200 μm. (E and F) Bar graphs of MVD 
in pancreatic tumors with and without BEV treatment. BEV significantly reduced the MVD of MiaPaCa-2 compared to the control (p = 
0.002) (E), but did not reduce the MVD of Panc-1 (F). ** p < 0.01. 
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was detected in the MiaPaCa-2 tumor after BEV → S. 
typhimurium A1-R treatment (Fig. 5). Our data suggest 
that S. typhimurium A1-R is able to survive and multiply 
even in the hypo-vascular area of the tumor treated with 
BEV and cause tumor shrinkage.
To further demonstrate the advantages of S. 
typhimurium A1-R treatment following anti-VEGF 
therapy in the orthotopic mouse model, 20 mice with 
MiaPaCa-2-GFP orthotopic tumors were established and 
randomized to 4 groups: (G1) saline (vehicle/control, 4 
weeks); (G2) GEM (4 weeks); (G3) BEV (4 weeks) / GEM 
(4 weeks) and (G4) BEV (2 weeks) / GEM (2 weeks) → S. 
typhimurium A1-R (2 weeks). Tumors were imaged and 
weighed after treatment (Fig. 6A). A large primary tumor 
and many metastases spreading over the entire abdominal 
cavity occurred in the control group (Fig. 6B; G1). Many 
metastases were found in the mice treated with GEM 
(G2) (Fig. 6B), but were rarely found in the BEV/GEM 
(G3) (Fig. 6B) and BEV/GEM → S. typhimurium A1-R 
groups (G4) (Fig. 6B; G4). The mean tumor weight of each 
group in the MiaPaCa-2-GFP model was as follows: (G1) 
Control: 2655.4 ± 583.9 mg; (G2) GEM: 775.9 ± 273.8 
mg; (G3) BEV/GEM: 413.5 ± 108.3 mg; (G4) BEV/GEM 
→ S. typhimurium A1-R: 257.5 ± 57.1 mg. All regimens 
significantly reduced tumor weight compared to the 
control group (G2: p < 0.001; G3: p < 0.001; G4: p = 0.001). 
BEV/GEM significantly reduced tumor weight compared 
to GEM (p = 0.038). BEV/GEM →S. typhimurium A1-R 
significantly reduced tumor weight compared to GEM 
(p = 0.012) and BEV/GEM (p = 0.029). These results 
demonstrate that BEV/GEM → S. typhimurium A1-R 
sequential combination therapy is more effective than the 
BEV/GEM combination. 
S. typhimurium A1-R following anti-VEGF 
therapy is effective in a VEGF-positive PDOX 
model
Our laboratory pioneered surgical orthotopic 
implantation (SOI) metastatic mouse models of patient 
tumor specimens in the early 1990s [18-24]. These  patient 
-derived orthotopic xenograft (PDOX) mouse models are 
more patient-like, especially with regard to metastasis, 
than ectopic subcutaneous models [25, 26].
A pancreatic cancer PDOX model was used to 
Figure 5: Distribution of GFP-labeled S. typhimurium A1-R bacteria in tumors and organs. Livers and tumors were minced 
and mixed with PBS, as was blood. The PBS, was plated on LB agar to identify S. typhimurium A1-R  GFP in each tissue. Fluorescent S. 
typhimurium A1-R colonies were observed with the OV100 Small Animal Imaging System (Olympus Corp., Tokyo, Japan). Representative 
images of GFP-labeled S. typhimurium A1-R cultured from the tumor and the normal organs (blood and liver) of the mice in the BEV → S. 
typhimurium A1-R and BEV → GEM groups. GFP-labeled S. typhimurium A1-R bacteria were clearly detected in both MiaPaCa-2 tumors 
(A) and Panc-1 tumors (B) in the BEV → S. typhimurium A1-R groups. No GFP-labeled S. typhimurium A1-R was detected in other tissues. 
Scale bars: 10 mm. BF= brightfield.
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determine the efficacy of S. typhimurium A1-R treatment 
following anti-VEGF therapy. The patient tumor was 
a moderately-differentiated adenocarcinoma which 
expressed VEGF (Fig. 7A). Twenty mice with PDOXs 
were established and randomized to 4 groups and treated 
in the same way as the GFP MiaPaCa-2 orthotopic model. 
A large primary tumor and some metastases occurred in 
the control group. A few metastases were found in the 
Figure 6: S. typhimurium A1-R treatment following BEV and GEM combination therapy of the MiaPaCa-2-GFP tumor in an 
orthotopic mouse model. (A) Schema of treatment of orthotopic MiaPaCa-2-GFP tumors. After confirmation of tumor growth by imaging 
with the OV100, the mice with orthotopic tumors were randomized to 4 groups: (G1) saline (vehicle/control, 4 weeks); (G2) GEM (4 
weeks); (G3) BEV (4 weeks) / GEM (4 weeks); and (G4) BEV (2 weeks) / GEM (2 weeks) → S. typhimurium A1-R (2 weeks). Animals 
underwent laparotomy on day 36, and the tumors were imaged with the OV100 and weighed and harvested for analysis. (B) Representative 
images at laparotomy. Upper panels indicate bright-field images (BF) and lower panels indicate GFP fluorescence images. A large primary 
tumor and many metastases spreading over the entire abdominal cavity were detected in the control group. Many metastases were found in 
the mice treated with GEM but rarely found in the BEV/GEM and BEV/GEM → S. typhimurium A1-R groups. All regimens significantly 
reduced tumor weight compared to the untreated control group (G2: p < 0.001; G3: p < 0.001; G4: p = 0.001). BEV/GEM significantly 
reduced tumor weight compared to GEM (p = 0.038). BEV/GEM → S. typhimurium A1-R significantly reduced tumor weight compared 
to GEM (p = 0.012) and BEV/GEM (p = 0.029).
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mice treated with GEM but rarely in the BEV/GEM and 
BEV/GEM → S. typhimurium A1-R groups (Fig. 7B). The 
mean tumor weight of each group in the PDOX model was 
as follows: (G1) Control: 998.8 ± 377.7 mg; (G2) GEM: 
263.1 ± 129.1 mg; (G3) BEV/GEM: 65.9 ± 41.9 mg; (G4) 
BEV/GEM →S. typhimurium A1-R: 21.9 ± 6.2 mg. All 
regimens significantly reduced tumor weight compared 
to the control group (G2: p = 0.004; G3: p = 0.002; G4: 
p = 0.001). BEV/GEM significantly reduced tumor 
weight compared to GEM (p = 0.005). BEV/GEM →S. 
typhimurium A1-R significantly reduced the tumor weight 
compared to GEM (p = 0.001) and BEV/GEM (p = 0.029). 
The results demonstrated in the PDOX model, BEV/GEM 
→ S. typhimurium A1-R sequential combination therapy 
was also more effective than the BEV/GEM combination.
Previously developed concepts and strategies 
of highly selective tumor-targeting [27-34] can take 
advantage of the S. typhimuium A1-R tumor targeting 
described in the present report.
MATERIALS AND METHODS
Cell culture and establishment of a green 
fluorescent protein-labeled cancer cell line
Human pancreatic cancer cell lines Panc-1, 
MiaPaCa-2 and Hs766T were maintained in Dulbecco’s 
modified Eagle’s medium (Invitrogen, Carlsbad, CA, 
USA). Human pancreatic cancer cell lines BxPC-3 and 
Capan-1 were maintained in RPMI-1640 (Invitrogen, 
Carlsbad, CA, USA). All cell lines were incubated at 
37°C in a humidified atmosphere containing 5% CO2. 
Each medium was supplemented with 10% fetal bovine 
serum, streptomycin, and penicillin (complete medium). 
The cells were collected after trypsinization and stained 
with trypan blue (Sigma-Aldrich, St. Louis, MO). Only 
viable cells which excluded trypan blue were counted 
Figure 7: S. typhimurium A1-R treatment following BEV and GEM combination therapy on a VEGF-positive pancreatic cancer 
PDOX. (A) Histological characterization of the PDOX. The PDOX was diagnosed as moderately-differentiated adenocarcinoma with H&E 
staining, and was strongly stained with an anti-VEGF antibody. Scale bars: 100 μm. (B) Representative images at laparotomy. The areas 
surrounded by the yellow broken lines indicate the primary tumors, and yellow arrow heads indicate metastasis. A large primary tumor and 
several metastases were detected in the control group (G1). A few metastases were found in the mice treated with GEM (G2) but rarely found 
in the BEV/GEM (G3) and BEV/GEM → S. typhimurium A1-R groups (G4). (C) Bar graphs of the total tumor weight (primary + metastasis) 
in each group. All regimens significantly reduced the tumor weight compared to the control group (G2: p = 0.004; G3: p = 0.002; G4: p = 
0.001). BEV/GEM significantly reduced tumor weight compared to GEM (p = 0.005). BEV/GEM → S. typhimurium A1-R significantly 
reduced the tumor weight compared to GEM (p = 0.001) and BEV/GEM (p = 0.029).
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with a hemocytometer (Hausser Scientific, Horsham, PA). 
For GFP gene transduction of cancer cells, 70% confluent 
human pancreatic cancer (MiaPaCa-2) cells were used. In 
brief, cells were incubated with a 1:1 precipitated mixture 
of retroviral supernatants of PT67-GFP packaging cells 
which express the GFP gene linked to the G418 resistance 
gene and RPMI 1640 (Irvine Scientific, Santa Ana, CA) 
containing 10% fetal bovine serum (FBS) (Hyclone 
Laboratories, Logan, UT) for 72 h. Fresh medium was 
replenished at this time. Cells were harvested with trypsin/
EDTA 72 h post-transduction and subcultured at a ratio 
of 1:15 into medium, which contained 200 µg/ml of the 
selective agent G418. The level of G418 was increased 
stepwise up to 800 µg/ml [35, 36].
Real-time RT-PCR
Total RNA was extracted from human pancreatic 
cancer cell lines (BxPC-3, Capan-1, Hs766T, MiaPaCa-2 
and Panc-1) using TRIzol (Invitrogen, Carlsbad, CA, 
USA), followed by on-column clean up with the RNA 
spin mini kit (GE Healthcare BioSciences, Little Chalfont, 
UK). Total RNA (2 μg) was reverse transcribed using the 
High Capacity RNA-to-cDNA kit (Applied Biosystems, 
Foster City, CA, USA) for complementary DNA (cDNA) 
synthesis. cDNA (2 µl) in a final volume of 20 μl,was 
amplified using the following Taqman Gene Expression 
assays (Applied Biosystems): VEGFA (Hs00900055_m1); 
VEGFR1 (Hs01052961_m1); VEGFR2 (Hs00911700_
m1); and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) endogenous control (Hs99999905_m1). All 
reactions were performed in triplicate using ABI 7900 
HT Fast (Applied Biosystems). Analysis of relative gene 
expression data used the ΔΔCt method. An example is 
shown below: 
Relative expression = 2 –ΔΔCt , ΔΔCt = (Ct, Target - Ct, 
GAPDH
 ) - (Ct, Panc-1 - Ct, GAPDH ).
Preparation of bacteria
S. typhimurium A1-R was grown overnight on LB 
medium and then diluted 1:10 in LB medium. Bacteria 
were harvested at late-log phase, washed with PBS, and 
then diluted in PBS for use in experiments [6].
Confocal imaging of cancer cells infected with S. 
typhimurium A1-R in vitro
Both MiaPaCa-2 and Panc-1 pancreatic cancer 
cell lines were infected with S. typhimurium A1-R GFP 
in vitro. Pancreatic cancer cells were grown in 24-well 
tissue culture plates to a density of approximately 104 
cells/well. S. typhimurium A1-R  GFP were grown to 
late log in LB broth, diluted in cell culture medium and 
added to the cancer cells (1×107 CFU/ml) and incubated 
at 37°C. After 40 min, the cells were rinsed and cultured 
in medium containing gentamycin sulfate (20 μg/ml) to 
kill external, but not internal bacteria. The interaction of 
S. typhimurium A1-R GFP with cancer cells in vitro was 
observed with confocal microscopy (Fluoview FV1000, 
Olympus, Tokyo, Japan). The excitation source was a 
semiconductor laser at 473 nm for GFP. Fluorescence 
images were obtained using the 20x/1.0 XLUMPLFLN 
objective [37].
Clonogenic assay
MiaPaCa-2 and Panc-1 cells (1×103) were seeded 
in 35 mm dishes. S. typhimurium A1-R (1×107 CFU/ml) 
was added to the cancer cells and incubated at 37°C. After 
40 min, the cells were rinsed and cultured in medium 
containing gentamycin sulfate (20 μg/ml). After 7-days 
culture, the cancer-cell colonies were fixed with ethanol 
and then stained with crystal violet. ImageJ was used to 
quantify the cell colonies.
Animals
Male athymic (nu/nu) nude mice (AntiCancer, Inc., 
San Diego) (4-6 weeks) were used in this study. Mice were 
kept in a barrier facility under HEPA filtration. Mice were 
fed with autoclaved laboratory rodent diet. All surgical 
procedures and imaging were performed with the animals 
anesthetized by intramuscular injection of a solution of 
50% ketamine, 38% xylazine, and 12% acepromazine 
maleate (0.02 ml). All animal studies were conducted in 
accordance with the principals and procedures outlined 
in the NIH Guide for the Care and Use of Laboratory 
Animals under PHS Assurance Number A3873-1.
Subcutaneous pancreatic cancer cell implantation
Panc-1 and MiaPaCa-2 pancreatic cancer cells 
were harvested by trypsinization and washed twice with 
serum-free medium. Cells (2×106 in 100 μl serum-free 
medium) were injected subcutaneously within 30 min 
of harvesting, over the right and left flanks in male nude 
mice. Subcutaneous tumors were allowed to grow for 2-4 
weeks until large enough for subsequent experiments or 
orthotopic implantation. 
Assessment of microvessel density (MVD) in 
xenograft tumors
Frozen tumor sections (7 μm) were fixed with 
methanol. The sections were then treated for 30 min 
with hydrogen peroxide (0.3%) to block endogenous 
peroxidase activity. After incubation with normal goat 
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serum 15%, the sections were incubated with anti-mouse 
CD31 (1:100; BD Pharmigen, San Jose, CA, USA) for 
1 hour at room temperature. The primary antibodies 
were detected using anti-rat secondary antibodies and 
avidin/biotin/horseradish peroxidase complex (Vector 
Laboratories, Burlingame, CA, USA) for 30 min at 
room temperature. The labeled antigens were visualized 
with the DAB kit (DAKO Cytomation, Kyoto, Japan). 
The sections were counterstained with hematoxylin and 
examined using a BH-2 microscope (Olympus) equipped 
with an INFINITY1 2.0 megapixel CMOS digital camera 
(Lumenera Corporation, Ottawa, Canada). All images 
were acquired using INFINITY ANALYZE software 
(Lumenera Corporation) without post-acquisition 
processing. MVD was determined by counting three fields 
at ×100 magnification of the highest vascular density.
Specimen collection
Patient pancreatic tumor samples were procured 
with informed written consent and the study was 
conducted under the approval of the Institutional Review 
Board of the UC San Diego Medical Center.
Orthotopic tumor implantation
A small transverse incision (6- to 10-mm) was 
made on the left flank of the mouse through the skin 
and peritoneum. The tail of the pancreas was exposed 
through this incision, and a single tumor fragment (3-
mm3.) harvested from a subcutaneous tumor was sutured 
to the tail of the pancreas using 8-0 nylon surgical sutures 
(Ethilon; Ethicon Inc., NJ, USA). On completion, the tail 
of the pancreas was returned to the abdomen, and the 
incision was closed in one layer using 6-0 nylon surgical 
sutures [19, 24].
Treatment
Mice were randomized to 4 groups and treated 
as follows: (G1) saline (vehicle/control, ip, weekly, 4 
weeks); (G2) GEM (Eli Lilly, Indianapolis, IN) (80 mg/
kg, ip, weekly, 4 weeks); (G3) BEV (Genentech, South 
San Francisco, CA)(5 mg/kg, ip, twice a week, 4 weeks) 
/ GEM (80 mg/kg, ip, weekly, 4 weeks) and (G4) BEV 
(5 mg/kg, ip, twice a week, 2 weeks) / GEM (80 mg/
kg, ip, weekly, 2 weeks) → S. typhimurium A1-R (5 × 
107 CFU/body, iv, weekly, 2 weeks) (Fig. 4A). Each 
treatment group comprised 5 tumor-bearing mice. Body 
weights of the mice were determined on a balance once 
a week. Tumor size was measured with calipers in the 
subcutaneous models, and at laparotomy in the orthotopic 
models on day 36. Tumors were imaged with an OV100 
Small Animal Imaging System (Olympus, Tokyo, Japan) 
or a Canon EOS 60D digital camera with an EF–S18–55 
IS lens (Canon, Tokyo, Japan) and weighed and harvested 
for analysis. 
Tissue histology
Tumor samples were removed with surrounding 
normal tissues at the time of resection. Fresh tissue 
samples were fixed in 10% formalin and embedded in 
paraffin before sectioning and staining. Tissue sections (3 
μm) were deparaffinized in xylene and rehydrated in an 
ethanol series. Hematoxylin and eosin (H & E) staining 
was performed according to standard protocols.
Fluorescence in vivo imaging
The OV100 Small Animal Imaging System, 
containing an MT-20 light source (Olympus Biosystems, 
Planegg, Germany) and DP70 CCD camera (Olympus) 
were used for imaging GFP-labeled S. typhimurium A1-R 
and orthotopic tumors in live mice [38].
Detection of GFP-labeled S. typhimurium A1-R 
bacteria in tumors and organs
Tissues from subcutaneous tumors and normal 
organs (blood, spleen and liver) were removed at 
termination from the nude mice with subcutaneous tumors. 
S. typhimurium A1-R was extracted from the tumors and 
organs and cultured in LB agar for 24 hours, and imaged 
with the Olympus OV100. 
Statistical analysis
PASW Statistics 18.0 (SPSS, Inc) was used for 
all statistical analyses. The Student’s t-test was used 
to compare continuous variables between two groups. 
Analysis of variance models were used to compare 
multiple groups. A p value of ≤ 0.05 was considered 
statistically significant for all comparisons.
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